Search Results for: c

2022-ASCO-Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results.

Publications /

2022-ASCO-Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, alone or with irinotecan, temozolomide/ irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: Interim results. Read More »

Cookie Policy

COOKIE POLICY Cookies are small text files that are placed on your device by websites that you visit. They are used to make websites work, or work more efficiently, as well as to provide information to the owners of the website. Our website uses strictly necessary cookies, functional cookies and tracking and performance cookies. Strictly

Cookie Policy Read More »

Accessibility

ACCESSIBILITY STATEMENT OUR COMMITMENT TO ACCESSIBILITY Actuate is committed to making our website accessible to everyone. We have built our website in a manner to work with assistive technologies using the Worldwide Web Consortium’s Website Content Accessibility Guidelines. Actuate continues to evaluate its website to maintain and expand its accessibility for all visitors. FEEDBACK If

Accessibility Read More »

CONTACT US

CONTACT US If you would like to partner with us, have media inquiries, or simply want to learn more, we want to hear from you. Fill out the form below to get in touch. US ADDRESS 1751 River Run, Suite 400 Fort Worth, TX 76107 EMAIL info@actuatetherapeutics.com EU ADDRESS The Black Church St. Mary’s Place

CONTACT US Read More »